Anthropic is preparing to turn demand for Claude into one of the year’s largest stock-market offerings. For investors, the question is becoming more specific: what price will they pay, and what exactly will they own?

The company’s proposed offering includes 825 million Class A shares at an expected $70–$78 each. At the $74 midpoint, that equals $61.05 billion in gross offering value, calculated before fees and any exercise of the underwriters’ additional-share option.

That total includes stock sold by existing holders. Anthropic is offering approximately 801.35 million shares; selling shareholders are offering about 23.65 million. At the midpoint, the company’s own portion would be roughly $59.30 billion before expenses. It will receive no proceeds from the shareholders’ sales.

A big offering in a less forgiving market

Reuters reported on November 17 that pricing was expected Wednesday, November 18, with trading due to begin Thursday. The planned Nasdaq ticker is ANT. Final pricing and the trading timetable remain subject to completion of the offering.

The offering arrives during a technology-stock selloff. As Blockster’s market report details, the Nasdaq has surrendered much of its 2026 advance, leaving a less forgiving backdrop for a new listing.

Blockster’s coverage of Claude Fable 5.2 focused on what builders could accomplish with the model. A public listing asks another question: how much of that usefulness turns into durable revenue and shareholder returns?

A widely used product does not settle the valuation question. Investors still need to examine the cost of serving customers, competitive pricing and the spending required to keep the models improving. The IPO price is where those expectations acquire a public reference point.

Three prices that should not be confused

An IPO allocation, a purchase after exchange trading starts and a pre-IPO derivative are separate routes to exposure.

RouteWhat the investor getsWhat determines the entry price
IPO allocationShares, if an allocation is receivedFinal offering price
Exchange purchase after listingShares purchased in the marketAvailable market price
OKX Pre-IPO X-PerpA cash-settled derivativeTrading in the derivative market

Eligible customers can already trade Anthropic-linked Pre-IPO X-Perps on OKX. These allow long or short exposure to a market-implied valuation, with leverage. They do not provide an IPO allocation, voting rights or a claim to future shares.

“Trading a Pre-IPO X-Perp does not make you a shareholder.”

— OKX, product guidance

That distinction stays relevant after the listing. OKX says it intends to transition the contract into a standard equity-linked X-Perp; the position remains a derivative. Its price can differ from the stock, and funding costs and liquidation risk affect the experience of holding it.

Access is only part of the investment question

Trading before a listing can reveal market sentiment, but a derivative’s price is not a binding forecast of the IPO price or the first public trade. Nor does being early guarantee a better entry point.

For anyone comparing these routes, the practical differences are ownership, funding costs and the possibility of liquidation. An IPO allocation can be hard to obtain; a leveraged derivative can be easier to enter but carries a different set of risks. The final offering price will provide a reference point, not a promise about where either market trades next.

Reporting by Sasha Steenkamp

AITrading